Dispatch Bio
Series A
€216M
Total Raised
€216M
Investors
Alexandria Venture Investments, ARCH Venture Partners, Bristol-Myers Squibb +3 more
Insights
In the biotechnology and health care sector, Dispatch Bio develops immunotherapy that treats solid tumors with the potential to significantly advance cancer treatment options. The company’s research targets a critical unmet need in oncology by engineering immune responses against hard-to-treat tumors. This approach has attracted backing from Bristol-Myers Squibb, ARCH Venture Partners, Alexandria Venture Investments, the Parker Institute for Cancer Immunotherapy, Stanford University and the University of Pennsylvania.
Careers at Dispatch Bio
Similar Companies
JumpArtificial Intelligence (AI), Financial Services, FinTech, Generative AI, SaaS, Wealth Management · Salt Lake City, Utah, United States, North America
OuttakeArtificial Intelligence (AI), Cyber Security, Machine Learning · Brooklyn, New York, United States, North America
GoodfireArtificial Intelligence (AI), Generative AI, Information Technology · San Francisco, California, United States, North America
Northwood SpaceAerospace, Hardware, Satellite Communication · Torrance, California, United States, North America
ZocksArtificial Intelligence (AI), Enterprise Software, Financial Services, Software · San Francisco, California, United States, North America
VulnCheckArtificial Intelligence (AI), Cyber Security, Information Technology, Network Security · Lexington, Massachusetts, United States, North America